Cell Cycle

KRAS inhibitor-4 (compound F12) is a potent inhibitor targeting KRAS, a critical regulator of cell signaling pathways. This compound exhibits significant anticancer activity by disrupting KRAS-mediated signaling, thereby inhibiting tumor growth and proliferation. It is a valuable tool for research focused on cancer biology and therapeutic development related to KRAS mutations.

KRAS Inhibitor-14 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting a potent IC50 of 0.249 µM. It effectively inhibits phosphorylated ERK (p-ERK) with IC50 values of 1.12 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. This compound is valuable for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers.

KRAS G12C inhibitor 29 is a selective inhibitor targeting the KRAS G12C mutation, which plays a critical role in various cancer types. This compound demonstrates significant activity in suppressing tumor growth in KRAS G12C-driven models, making it a valuable tool for cancer research. It is particularly useful for studies focused on understanding KRAS-related signaling pathways and developing targeted therapies.

Neogrifolin is a selective inhibitor of KRAS, which plays a critical role in the signaling pathways associated with cancer cell proliferation and survival. This compound has demonstrated significant anti-cell viability activity against human cancer cell lines, including HeLa (IC50: 24.3 μM), SW480 (IC50: 34.6 μM), and HT29 (IC50: 30.1 μM). Neogrifolin is primarily utilized in research applications aimed at elucidating the role of KRAS in tumorigenesis and investigating potential therapeutic strategies for KRAS-driven malignancies.

NSC1011 is a selective inhibitor of Ras converting enzyme 1 (Rce1), demonstrating an IC50 of 6.9 µM against the human Rce1. This compound disrupts the localization of key Ras proteins, including EGFR-H-Ras, EGFR-N-Ras, and EGFR-K-Ras. NSC1011 is valuable for research on Ras signaling pathways and their implications in cancer biology.

K-Ras-IN-3 is a selective inhibitor of GDP-bound K-Ras G12V, exhibiting an IC50 value of 0.371 nM. This compound demonstrates significant potential for cancer research, particularly in the study of K-Ras-driven tumors and their associated signaling pathways. Its specificity enables investigations into K-Ras's role in oncogenesis and therapy resistance.

CDK7 ligand 2 is a selective inhibitor targeting CDK7, a crucial cyclin-dependent kinase involved in transcription regulation. This compound exhibits significant potential in drug discovery and development, particularly in the synthesis of PROTACs (Proteolysis Targeting Chimeras). Its application in research may facilitate novel therapeutic approaches for diseases associated with abnormal transcriptional control.

CDK9 ligand 4 functions as a potent ligand for cyclin-dependent kinase 9 (CDK9). This compound is instrumental in the design and development of PROTAC-based degraders, facilitating targeted degradation of CDK9 proteins, which plays a crucial role in transcriptional regulation and HIV-1 infection research. CDK9 ligand 4 contributes significantly to studies aimed at therapeutic strategies against viral infections and dysregulated transcriptional processes.

CDK4 Degrader 1 (ML 1–71) is a molecular glue degrader that specifically targets cyclin-dependent kinase 4 (CDK4). This compound promotes the selective degradation of CDK4, leading to reduced cell proliferation and induction of cell cycle arrest in various cancer models. It serves as a valuable tool for investigating CDK4's role in tumorigenesis and for the development of targeted therapies in cancer research.

HZ1 is a selective inhibitor of cyclin-dependent kinase-like 3 (CDKL3) that operates via targeted inhibition of this kinase. It demonstrates significant tumor-suppressive activity and has potential to circumvent resistance to CDK4/6 inhibitors. This compound is applicable in cancer research, particularly in studies focused on cell cycle regulation and therapeutic resistance mechanisms.

PROTAC CDK9 degrader-4 is a potent CDK9 degradation agent that facilitates the targeted degradation of cyclin-dependent kinase 9. This compound effectively modulates transcriptional regulation by harnessing the power of PROTAC technology, leading to significant biological activity in various cellular contexts. It holds potential applications in cancer research and the study of transcriptional control mechanisms.

PROTAC DYRK2 degrader 1 is a selective degrader targeting DYRK2, functioning through the ubiquitin-proteasome system. It exhibits DC50 values of 1.607 μM in MDA-MB-231 cells and 3.265 μM in HeLa cells, effectively inducing DYRK2 degradation. This compound is valuable for research focused on triple-negative breast cancer and cervical cancer, facilitating the exploration of targeted protein degradation mechanisms in these malignancies.

Ribociclib succinate is an orally active inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), functioning through ATP-competitive mechanisms. It demonstrates potent activity with IC50 values of 10 nM and 39 nM against CDK4 and CDK6, respectively, while exhibiting over 1,000-fold selectivity against the cyclin B/CDK1 complex. This selectivity makes it a valuable tool in cancer research, particularly in studies targeting cell cycle regulation and therapeutic strategies for hormone receptor-positive breast cancer.

Ribociclib succinate hydrate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), functioning through competitive inhibition of ATP binding. With IC50 values of 10 nM and 39 nM against CDK4 and CDK6, respectively, it demonstrates significant selectivity over the cyclin B/CDK1 complex. This compound is utilized in cancer research, particularly in studies focusing on cell cycle regulation, tumor proliferation, and the therapeutic potential in various malignancies. Its ability to cross the blood-brain barrier allows for exploration in central nervous system-related cancers.

PROTAC CDK2-pRb degrader-1 is an orally active PROTAC that targets cyclin-dependent kinase 2 (CDK2) for degradation. This compound effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine 807/811 by promoting the ubiquitination and proteasomal degradation of CDK2. Demonstrating significant biological activity with EC50 values of 12 nM and 125 nM in human cells, PROTAC CDK2-pRb degrader-1 is particularly useful in research focused on CCNE1-amplified cancers, including ovarian, gastric, and breast cancers, as it inhibits tumor growth and induces tumor stasis in xenograft models.